Status:
COMPLETED
A New Quantitative Fecal Immunochemical Test in Detecting Colorectal Advanced Adenoma
Lead Sponsor:
Shandong University
Conditions:
Colorectal Adenoma
Colorectal Neoplasm
Eligibility:
All Genders
50-75 years
Brief Summary
Early detecting and removing of colorectal advanced adenomas can reduce incidence of colorectal cancer. Because of the less bleeding of advanced adenomas, the sensitivity of existing quantitative feca...
Detailed Description
Colorectal cancer accounts for approximately 10% of all annually diagnosed cancers and cancer-related deaths worldwide. With progress of developing countries, it is predicted that the incidence of col...
Eligibility Criteria
Inclusion
- 50-75 years old people;
- People sign an "informed consent form"
Exclusion
- People with history of surgery in any part of the large bowel;
- People with history of colorectal cancer;
- People with history of other diseases that may produce fecal blood, such as active diverticulitis, inflammatory bowel disease, ischemic enteritis, vascular malformation of intestine, intestinal tuberculosis or Non-Hodgkin's lymphoma involving digestive tract;
- People with symptoms including visible rectal bleeding, hematuria, hemorrhoid bleeds, severe and acute diarrhea and 7th type stool (Bristol feces score);
- People are in pregnancy, lactation or menstrual phase;
- People with severe congestive heart failure or other sever disease cause cannot tolerate colonoscopy.
Key Trial Info
Start Date :
August 17 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 11 2021
Estimated Enrollment :
1600 Patients enrolled
Trial Details
Trial ID
NCT04473677
Start Date
August 17 2020
End Date
June 11 2021
Last Update
June 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu Hospital
Jinan, Shandong, China, 250001